FDA's Yim Wants US To Emulate Europe On Biosimilars
Hopes To See European-Like Robustness For US Market In 10 Years
In an exclusive interview with Generics Bulletin sister publication the Pink Sheet, the now-permanent OTBB director Sarah Yim discussed her expectations for the future of the US biosimilars market, her learning experience as acting director and upcoming challenges for her office.
